Eli Lilly’s pill lagged behind Novo Nordisk in its first week. Why did the stock rise?investor’s business daily
Eli Lilly just got some good news about its weight loss pillWSJ
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundaio (orfoglipron) to date, confirms its cardiovascular and overall safety profile as well as consistent improvements in key measures of cardiometabolic health.Eli Lilly and Company
Lilly’s obesity pill receives 1,390 US prescriptions in launch weekreuters
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more databiospace
